vs

Side-by-side financial comparison of CVB FINANCIAL CORP (CVBF) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

CVB FINANCIAL CORP is the larger business by last-quarter revenue ($133.8M vs $75.5M, roughly 1.8× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 8.4%). CVB FINANCIAL CORP produced more free cash flow last quarter ($217.3M vs $14.4M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 2.8%).

CVB Financial Corp is a U.S. bank holding company operating Citizens Business Bank, serving mainly California markets. It offers commercial banking, personal banking and wealth management solutions for small to medium enterprises, professional firms and individual consumers, with core services including loans, deposit accounts and asset management.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

CVBF vs PBYI — Head-to-Head

Bigger by revenue
CVBF
CVBF
1.8× larger
CVBF
$133.8M
$75.5M
PBYI
Growing faster (revenue YoY)
PBYI
PBYI
+19.4% gap
PBYI
27.7%
8.4%
CVBF
More free cash flow
CVBF
CVBF
$203.0M more FCF
CVBF
$217.3M
$14.4M
PBYI
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
2.8%
CVBF

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CVBF
CVBF
PBYI
PBYI
Revenue
$133.8M
$75.5M
Net Profit
Gross Margin
69.3%
Operating Margin
55.6%
22.7%
Net Margin
Revenue YoY
8.4%
27.7%
Net Profit YoY
EPS (diluted)
$0.41
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CVBF
CVBF
PBYI
PBYI
Q4 25
$133.8M
$75.5M
Q3 25
$128.6M
$54.5M
Q2 25
$126.4M
$52.4M
Q1 25
$126.7M
$46.0M
Q4 24
$123.5M
$59.1M
Q3 24
$126.5M
$80.5M
Q2 24
$125.3M
$47.1M
Q1 24
$126.6M
$43.8M
Net Profit
CVBF
CVBF
PBYI
PBYI
Q4 25
Q3 25
$52.6M
$8.8M
Q2 25
$50.6M
$5.9M
Q1 25
$51.1M
$3.0M
Q4 24
Q3 24
$51.2M
$20.3M
Q2 24
$50.0M
$-4.5M
Q1 24
$48.6M
$-4.8M
Gross Margin
CVBF
CVBF
PBYI
PBYI
Q4 25
69.3%
Q3 25
77.7%
Q2 25
76.5%
Q1 25
77.1%
Q4 24
76.4%
Q3 24
63.9%
Q2 24
77.4%
Q1 24
75.5%
Operating Margin
CVBF
CVBF
PBYI
PBYI
Q4 25
55.6%
22.7%
Q3 25
53.7%
17.6%
Q2 25
54.4%
12.7%
Q1 25
54.9%
8.7%
Q4 24
55.1%
22.6%
Q3 24
53.5%
27.4%
Q2 24
54.9%
-4.6%
Q1 24
52.8%
-5.3%
Net Margin
CVBF
CVBF
PBYI
PBYI
Q4 25
Q3 25
40.9%
16.2%
Q2 25
40.0%
11.2%
Q1 25
40.3%
6.5%
Q4 24
Q3 24
40.5%
25.2%
Q2 24
39.9%
-9.6%
Q1 24
38.4%
-11.0%
EPS (diluted)
CVBF
CVBF
PBYI
PBYI
Q4 25
$0.41
$0.26
Q3 25
$0.38
$0.17
Q2 25
$0.37
$0.12
Q1 25
$0.36
$0.06
Q4 24
$0.36
$0.40
Q3 24
$0.37
$0.41
Q2 24
$0.36
$-0.09
Q1 24
$0.35
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CVBF
CVBF
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$376.4M
$97.5M
Total DebtLower is stronger
$22.7M
Stockholders' EquityBook value
$2.3B
$130.3M
Total Assets
$15.6B
$216.3M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CVBF
CVBF
PBYI
PBYI
Q4 25
$376.4M
$97.5M
Q3 25
$783.9M
$94.4M
Q2 25
$738.6M
$96.0M
Q1 25
$529.1M
$93.2M
Q4 24
$204.7M
$101.0M
Q3 24
$453.5M
$96.7M
Q2 24
$844.2M
$96.8M
Q1 24
$949.6M
$107.2M
Total Debt
CVBF
CVBF
PBYI
PBYI
Q4 25
$22.7M
Q3 25
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
Q4 24
$68.0M
Q3 24
$79.3M
Q2 24
$90.7M
Q1 24
$102.0M
Stockholders' Equity
CVBF
CVBF
PBYI
PBYI
Q4 25
$2.3B
$130.3M
Q3 25
$2.3B
$115.3M
Q2 25
$2.2B
$104.7M
Q1 25
$2.2B
$97.1M
Q4 24
$2.2B
$92.1M
Q3 24
$2.2B
$71.1M
Q2 24
$2.1B
$48.5M
Q1 24
$2.1B
$51.0M
Total Assets
CVBF
CVBF
PBYI
PBYI
Q4 25
$15.6B
$216.3M
Q3 25
$15.7B
$202.9M
Q2 25
$15.4B
$194.9M
Q1 25
$15.3B
$196.2M
Q4 24
$15.2B
$213.3M
Q3 24
$15.4B
$220.7M
Q2 24
$16.2B
$205.0M
Q1 24
$16.5B
$214.1M
Debt / Equity
CVBF
CVBF
PBYI
PBYI
Q4 25
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.74×
Q3 24
1.12×
Q2 24
1.87×
Q1 24
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CVBF
CVBF
PBYI
PBYI
Operating Cash FlowLast quarter
$221.4M
$14.4M
Free Cash FlowOCF − Capex
$217.3M
$14.4M
FCF MarginFCF / Revenue
162.4%
19.1%
Capex IntensityCapex / Revenue
3.0%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$391.5M
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CVBF
CVBF
PBYI
PBYI
Q4 25
$221.4M
$14.4M
Q3 25
$81.5M
$9.7M
Q2 25
$53.1M
$14.1M
Q1 25
$41.9M
$3.6M
Q4 24
$249.8M
$15.6M
Q3 24
$71.4M
$11.0M
Q2 24
$26.1M
$1.0M
Q1 24
$77.5M
$11.2M
Free Cash Flow
CVBF
CVBF
PBYI
PBYI
Q4 25
$217.3M
$14.4M
Q3 25
$80.7M
$9.7M
Q2 25
$52.3M
$14.1M
Q1 25
$41.2M
$3.6M
Q4 24
$244.6M
$15.6M
Q3 24
$70.2M
$11.0M
Q2 24
$24.4M
$1.0M
Q1 24
$77.3M
FCF Margin
CVBF
CVBF
PBYI
PBYI
Q4 25
162.4%
19.1%
Q3 25
62.8%
17.7%
Q2 25
41.4%
26.8%
Q1 25
32.5%
7.7%
Q4 24
198.0%
26.4%
Q3 24
55.5%
13.7%
Q2 24
19.5%
2.1%
Q1 24
61.1%
Capex Intensity
CVBF
CVBF
PBYI
PBYI
Q4 25
3.0%
0.0%
Q3 25
0.7%
0.0%
Q2 25
0.7%
0.0%
Q1 25
0.5%
0.1%
Q4 24
4.2%
0.0%
Q3 24
1.0%
0.0%
Q2 24
1.4%
0.0%
Q1 24
0.1%
0.0%
Cash Conversion
CVBF
CVBF
PBYI
PBYI
Q4 25
Q3 25
1.55×
1.10×
Q2 25
1.05×
2.41×
Q1 25
0.82×
1.21×
Q4 24
Q3 24
1.39×
0.54×
Q2 24
0.52×
Q1 24
1.59×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons